- Home
- / Arch Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Arch Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Total Funding
$5.9 M
Revenue
$75.7 K
FY, 2023
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.6K | 15.7K | 75.7K | |||||||||
| Cost of goods sold | 26.3K | 51.5K | 78.2K | |||||||||
| Gross profit | (35.8K) | (2.4K) | ||||||||||
| Gross profit margin, % | -229.0% | -3.2% | ||||||||||
| General and administrative expense | 36.6K | 1.5M | 3.1M | 3.7M | 4.4M | 5.2M | 4.6M | 4.0M | 3.8M | 5.0M | 4.5M | 4.4M |
| Operating expense total | 36.6K | 1.7M | 4.6M | 5.5M | 6.1M | 7.3M | 7.4M | 6.4M | 5.4M | 6.4M | 5.7M | 5.0M |
| EBIT | (1.7M) | (4.6M) | (5.5M) | (6.1M) | (7.3M) | (7.4M) | (6.4M) | (5.4M) | (6.4M) | (5.7M) | (5.0M) | |
| EBIT margin, % | -36473.3% | -6661.7% | ||||||||||
| Interest expense | 3.1M | |||||||||||
| Pre tax profit | (36.6K) | |||||||||||
| Net Income | (36.6K) | (1.9M) | (8.1M) | (2.9M) | (6.0M) | (7.8M) | (4.8M) | (4.5M) | (4.7M) | (6.2M) | (5.3M) | (7.0M) |